RNA
USDAvidity Biosciences Inc. Common Stock
即時價格
價格圖表
關鍵指標
市場指標
開盤
$69.780
最高
$69.870
最低
$69.760
交易量
7.06M
公司基本面
市值
10.3B
行業
生物科技
國家
United States
交易統計
平均交易量
5.20M
交易所
NGM
貨幣
USD
52週範圍
相關新聞
Halper Sadeh LLC Encourages RNA, JAMF, AWK Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
TD Cowen Downgrades Avidity Biosciences to Hold, Lowers Price Target to $74
TD Cowen analyst Ritu Baral downgrades Avidity Biosciences from Buy to Hold and lowers the price target from $78 to $74.
Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders
The Ademi Firm is investigating Avidity (Nasdaq: RNA) for possible breaches of fiduciary duty and other violations of law in its transaction with...
Chardan Capital Downgrades Avidity Biosciences to Neutral, Lowers Price Target to $72
Chardan Capital analyst Keay Nakae downgrades Avidity Biosciences from Buy to Neutral and lowers the price target from $75 to $72.
RBC Capital Downgrades Avidity Biosciences to Sector Perform, Raises Price Target to $72
RBC Capital analyst Luca Issi downgrades Avidity Biosciences from Outperform to Sector Perform and raises the price target from $61 to $72.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avidity Biosciences, Inc. (NASDAQ: RNA)
Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for...
Avidity Biosciences Soars After $72 Per Share Novartis Takeover
Avidity Biosciences to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright downgrades to Neutral.
